US Patent

US11351182 — Vaginal inserted estradiol pharmaceutical compositions and methods

Method of Use · Assigned to TherapeuticsMD Inc · Expires 2032-11-21 · 7y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions of solubilized estradiol in soft capsules for vaginal insertion to treat vulvovaginal atrophy.

USPTO Abstract

According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.

Drugs covered by this patent

Estrace (ESTRADIOL) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2316`	—	Estrace
`U-2316`	—	Estrace

Patent Metadata

Patent number: US11351182
Jurisdiction: US
Classification: Method of Use
Expires: 2032-11-21
Drug substance claim: No
Drug product claim: No
Assignee: TherapeuticsMD Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.